Business
Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility
Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility C...
About this update from Aurora Cannabis Inc.
[{"type":"text","content":"\n \n \n \n Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Company's Long-Standing Investment in the Region Continues with Enhanced Local Production and Domestic Cultivar Research\n \n \n \n \n \n EDMONTON, AB\n \n \n ,\n \n \n July 25, 2024\n \n \n /CNW/ - Aurora Cannabis Inc. (the \"\n \n Company\n \n \" or \"\n \n Aurora\n \n \") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under\n \n Germany's\n \n new Medical Cannabis Act (MedCanG). Aurora's license grants the company continued domestic cultivation, which has been underway for two years now. Under the new license, Aurora may also cultivate an approved additional product, and plans to expand their offerings to the rapidly growing German patient base. Aurora will also receive a dedicated R&D license, allowing for the trial of up to seven additional novel cultivars at the company's local EU GMP facility in Leuna,\n \n Germany\n \n .\n \n \n \n \n \n \n \n \n \n \"We thank the German government for its continued investment in the growth of medical cannabis, made possible by decriminalization, which will improve access to medical cannabis for patients all across\n \n Germany\n \n ,\" says\n \n Michael Simon\n \n , President,\n \n Aurora Europe\n \n . \"Being one of the few companies to receive enhanced licenses is a testament to Aurora's established leadership in the region and unparalleled commitment to making available the highest quality cannabis. We now have the framework to extend our portfolio, invest in domestic research and leverage Aurora's global cultivation expertise locally.\"\n \n \n Aurora is committed to the growth, acceptance and broader access to medical cannabis globally. The company's leadership in\n \n Europe\n \n is a result of ongoing collaboration with government, regulators and industry. Since 2021, Au...